Filing Flows › Pacific Biosciences of California (PACB) › Q1 2025
Pacific Biosciences of California (PACB) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Pacific Biosciences of California (PACB) reported revenue of $37.2M for the first quarter 2025 (Q1 2025), -4% from a year earlier and -5% from the quarter before.
Pacific Biosciences of California, Q1 2025: revenue $37.2M (-4% year over year), net loss $426M, operating cash flow −$44.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $37.2M | -5% | -4% |
| Operating profit | −$429M | — | — |
| Net earnings | −$426M | — | — |
| Operating cash flow | −$44.1M | — | — |
What changed
Revenue was $37.2M in Q1 2025, down 4% year over year and down 5% from the previous quarter. Consumable revenue was the largest line at 54% of revenue. Instrument revenue lost $8.0M year over year (down 42%), 483% of the total change.
Operating costs exceeded revenue by $428.9M, an operating margin of -1154.5%. The fastest-growing cost line was Other operating costs (+6492%). The quarter ended with a net loss of $426.1M, after a profit of $2.4M the previous quarter.
Operating cash flow was −$44.1M. Non-cash charges added back $371.5M of depreciation and amortization and $9.2M of share-based compensation. Capital expenditures of $1.4M exceeded it, leaving free cash flow of −$45.4M.
Questions
What was Pacific Biosciences of California's revenue in the first quarter 2025?
Pacific Biosciences of California (PACB) reported revenue of $37.2M for the first quarter 2025 (Q1 2025), -4% from a year earlier and -5% from the quarter before.
Source: Pacific Biosciences of California 10-Q on SEC EDGAR.